ROCKET PHARMACEUTICALS, INC. financial data

Symbol
RCKT, RCKTW on Nasdaq
Location
New York, NY
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 802 % +1.4%
Debt-to-equity 15.8 % +1.47%
Return On Equity -62.4 % +0.29%
Return On Assets -53.9 % +0.48%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 108M shares +18.7%
Common Stock, Shares, Outstanding 108M shares +18.8%
Entity Public Float 1.4B USD +16.7%
Common Stock, Value, Issued 1.08M USD +18.8%
Weighted Average Number of Shares Outstanding, Basic 112M shares +18.5%
Weighted Average Number of Shares Outstanding, Diluted 112M shares +18.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 150M USD -14.6%
General and Administrative Expense 97.2M USD -1.02%
Operating Income (Loss) -250M USD +8.52%
Net Income (Loss) Attributable to Parent -241M USD +6.65%
Earnings Per Share, Basic -2 USD/shares +17.6%
Earnings Per Share, Diluted -2 USD/shares +17.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 75.9M USD +15.8%
Cash, Cash Equivalents, and Short-term Investments 223M USD -5.47%
Assets, Current 228M USD -5.82%
Property, Plant and Equipment, Net 29.8M USD -22.7%
Operating Lease, Right-of-Use Asset 3.65M USD -16%
Intangible Assets, Net (Excluding Goodwill) 25.2M USD 0%
Goodwill 39.2M USD 0%
Assets 368M USD -6.52%
Employee-related Liabilities, Current 11.4M USD +10.8%
Liabilities, Current 31.2M USD -22%
Operating Lease, Liability, Noncurrent 2.76M USD -19.2%
Other Liabilities, Noncurrent 1.06M USD -7.09%
Liabilities 54.4M USD -14.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -9K USD -104%
Retained Earnings (Accumulated Deficit) -1.4B USD -20.8%
Stockholders' Equity Attributable to Parent 314M USD -4.88%
Liabilities and Equity 368M USD -6.52%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -55.8M USD +1.88%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities -58M USD -266%
Common Stock, Shares Authorized 180M shares 0%
Common Stock, Shares, Issued 108M shares +18.8%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 77.3M USD +15.5%
Deferred Tax Assets, Valuation Allowance 129M USD +19%
Operating Lease, Liability 3.77M USD -14.6%
Payments to Acquire Property, Plant, and Equipment 364K USD -82.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -241M USD +6.3%
Lessee, Operating Lease, Liability, to be Paid 4.96M USD -16.9%
Property, Plant and Equipment, Gross 57.2M USD -1.26%
Operating Lease, Liability, Current 1.02M USD +1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 759K USD -24.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.01M USD +0.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.18M USD -23.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 522K USD -31.2%
Deferred Tax Assets, Operating Loss Carryforwards 67.6M USD +49.2%
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 539K USD +3.26%
Operating Lease, Payments 364K USD +9.31%
Additional Paid in Capital 1.71B USD +15.1%
Depreciation, Depletion and Amortization 2.7M USD +42.1%
Share-based Payment Arrangement, Expense 42M USD -1.7%
Interest Expense 1.89M USD +0.43%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%